Adaptive Biotechnologies Corp. Hits New 52-Week High of $26.15

Adaptive Biotechnologies Corp. has reached a significant milestone by hitting a new 52-week high of USD 26.15 on August 10, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 629.23% rise over the past year, significantly outpacing the S&P 500's performance of 21.34% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology industry, Adaptive Biotechnologies Corp. has demonstrated substantial growth potential. With a market capitalization of USD 1,911 million, the company continues to navigate the competitive landscape of its sector. Despite being loss-making, the stock's impressive price-to-book ratio of 8.73 indicates a strong valuation relative to its assets. The stock's previous 52-week low was USD 11.92, highlighting the extent of its upward trajectory. Investors and market observers will be keen to monitor how Adaptive Biotechnologies Corp. capitalizes on this momentum in the evolving biotechnology landscape.